| Abstract: |
The treatment of advanced renal cell carcinoma (RCC) has changed during the past 15 years, and a new treatment paradigm is in place. Targeted agents including sunitinib, sorafenib, pazopanib, axitinib, temsirolimus, everolimus, and bevacizumab are now utilized for patients with advanced and metastatic clear-cell carcinoma. Inhibition of a variety of targets including kinase receptors and their ligands such as vascular endothelial cell growth factor (VEGF) or the intracellular kinase mTOR (mammalian target of rapamycin) is in part responsible for the clinical efficacy of these agents. The agents approved as of 2013 by regulatory agencies for therapy of advanced renal cell carcinoma, either directly or indirectly, inhibit the VEGF pathway.The third edition of Renal Cell Carcinoma: Molecular Targets and Clinical Applications provides a review of advanced RCC and therapy available for patients and importantly reviews the validated and potential molecular targets identified in RCC. The ongoing evolution of this new treatment paradigm and development of multiple targeted agents with significant clinical activity in patients with advanced clear-cell carcinoma prompted this undertaking. Additionally, recent data investigating the molecular effects of therapy, the identification of new targets, and the progress in attempts to "personalize" RCC treatment are discussed. © Springer Science+Business Media New York 2015. |
